Cannabis products with THC showed small pain improvements with significant side effects, while CBD alone did not help

A living systematic review found THC:CBD sprays and high-THC products produced small pain reductions (mostly neuropathic), while CBD alone showed no benefit, and all THC products increased dizziness, sedation, and nausea.

Chou, Roger et al.·Pain and therapy·2025·Strong EvidenceMeta-Analysis
RTHC-06220Meta AnalysisStrong Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Meta-Analysis
Evidence
Strong Evidence
Sample
N=2,579

What This Study Found

THC:CBD oral spray: small pain decrease (MD -0.54/10); high THC: small decrease (MD -0.78/10); CBD alone: no benefit (moderate SOE); THC products caused large dizziness increase (RR 3.57) and sedation increase (RR 5.04).

Key Numbers

29 RCTs, N=2,579; THC:CBD spray MD -0.54 (95% CI -0.95 to -0.19); high THC MD -0.78 (-1.59 to -0.08); CBD alone MD 0.40 (no benefit); dizziness RR 3.57; sedation RR 5.04.

How They Did This

Living systematic review; 29 RCTs (N=2,579) and 15 observational studies (N=49,453); databases searched through April 2025; meta-analyses grouped by THC:CBD ratio and product type.

Why This Research Matters

This is the most current synthesis of cannabis for pain, showing benefits are small and limited to THC products while CBD alone does not help.

The Bigger Picture

Despite widespread belief in cannabis for pain, evidence shows modest THC-driven benefits weighed against substantial side effects, with no support for CBD-only products.

What This Study Doesn't Tell Us

Most studies short-term (1-6 months); 48% neuropathic pain; no evidence for psychosis, CUD, or cognitive harms; insufficient evidence for whole-plant cannabis.

Questions This Raises

  • ?Is a 0.5-0.8 point reduction clinically meaningful?
  • ?Would longer trials show tolerance?
  • ?Can side effects be managed to make small benefits worthwhile?

Trust & Context

Key Stat:
CBD alone produced no pain benefit, while THC products increased dizziness risk 3.6x
Evidence Grade:
Comprehensive living review with moderate strength of evidence, updated through April 2025.
Study Age:
Published 2025, updated through April 2025
Original Title:
Cannabinoids as a Potential Alternative to Opioids in the Management of Various Pain Subtypes: Benefits, Limitations, and Risks.
Published In:
Pain and therapy, 12(2), 355-375 (2025)
Database ID:
RTHC-06220

Evidence Hierarchy

Meta-Analysis / Systematic ReviewCombines many studies into one answer
This study
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal Study

Combines results from multiple studies to find an overall pattern.

What do these levels mean? →

Frequently Asked Questions

Does cannabis help with pain?

THC-containing products produced small reductions mostly for neuropathic pain. CBD alone showed no benefit.

What are the side effects?

THC products caused large increases in dizziness (3.6x) and sedation (5x), and moderate nausea increases. These are significant relative to the small pain benefit.

Read More on RethinkTHC

Cite This Study

RTHC-06220·https://rethinkthc.com/research/RTHC-06220

APA

Chou, Roger; Ahmed, Azrah Y.; Dana, Tracy; Morasco, Benjamin J.; Bougatsos, Christina; Fu, Rongwei; Williams, Leah; Ang, Samuel P; Sidharthan, Shawn; Lai, Wilson; Hussain, Nasir; Patel, Kiran V; Gulati, Amitabh; Henry, Onyeaka; Kaye, Alan D; Orhurhu, Vwaire. (2025). Cannabinoids as a Potential Alternative to Opioids in the Management of Various Pain Subtypes: Benefits, Limitations, and Risks.. Pain and therapy, 12(2), 355-375. https://doi.org/10.23970/AHRQEPCCER250UPDATE2025

MLA

Chou, Roger, et al. "Cannabinoids as a Potential Alternative to Opioids in the Management of Various Pain Subtypes: Benefits, Limitations, and Risks.." Pain and therapy, 2025. https://doi.org/10.23970/AHRQEPCCER250UPDATE2025

RethinkTHC

RethinkTHC Research Database. "Cannabinoids as a Potential Alternative to Opioids in the Ma..." RTHC-06220. Retrieved from https://rethinkthc.com/research/chou-2025-cannabinoids-as-a-potential

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.